GIOTRIF® :
The 1^st choice in 1^st-line

Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1^st-line EGFR M+ NSCLC^1-4*

GIOTRIF® for the treatment of NSCLC harbouring uncommon EGFR mutations: a published pooled analysis of 693 cases1*

Document ID: PC-MY-102826

03/02/2023

Author: Boehringer Ingelheim

123,000
Views

100k 340